{"nctId":"NCT01229397","briefTitle":"Immunogenicity and Safety of a Single 0.5 mL Dose of Inflexal V With a 0.25 mL 2-dose Regimen of Inflexal V","startDateStruct":{"date":"2010-10"},"conditions":["Influenza"],"count":205,"armGroups":[{"label":"Inflexal V 0.25 mL x 2","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Inflexal V"]},{"label":"Inflexal V 0.5 mL x 1","type":"EXPERIMENTAL","interventionNames":["Biological: Inflexal V"]}],"interventions":[{"name":"Inflexal V","otherNames":[]},{"name":"Inflexal V","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy male and female children\n* Aged ≥6 to \\<36 months on Day 1\n* Born at a gestational age ≥37 weeks\n* Written informed consent\n* No previous influenza vaccination\n\nExclusion Criteria:\n\n* Acute respiratory infection or other acute disease\n* Acute febrile illness (≥38.0 °C)\n* Past vaccination with an influenza vaccine, including vaccination against the influenza strain A/California/7/2009 (H1N1)-like virus\n* Laboratory-confirmed infection with any influenza strain, including the pandemic influenza strain H1N1 (A/California/7/2009 (H1N1)-like virus)\n* Known hypersensitivity to any vaccine component\n* Known history of egg protein allergy or severe atopy\n* Known blood coagulation disorder\n* Chronic (longer than 14 days) administration of immunosuppressants or other immune-modifying drugs within 6 months before the first dose of the study vaccine, incl. oral corticosteroids in dosages of ≥0.5 mg/kg/d prednisolone or equivalent for ≥14 days (inhaled or topical steroids are allowed)\n* Known immunodeficiency (including leukemia, cancer, HIV seropositivity)\n* Investigational medicinal product received in the past 3 months (90 days)\n* Treatment with immunoglobulins or blood transfusion(s) received in the past 3 months (90 days)\n* Vaccination with the MMR vaccine in the past 4 weeks, or planned within the study period\n* Participation in another clinical trial\n* Child or legal charge of the investigator or an employee at the study site, or living in the same household as the investigator/employee and/or dependent on the investigator/employee\n* Suspected non-compliance","healthyVolunteers":true,"sex":"ALL","minimumAge":"6 Months","maximumAge":"35 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Immunogenicity of a Single Full (0.5 mL) Dose and a 0.25 mL 2-dose Regimen of Inflexal V, Using the EMA Guideline for the Re-registration of the Seasonal Influenza Vaccine in Adults (Aged ≥18 to ≤60 Years) as Reference","description":"Seroprotection rate","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.0","spread":null},{"groupId":"OG001","value":"98.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.0","spread":null},{"groupId":"OG001","value":"97.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.2","spread":null},{"groupId":"OG001","value":"86.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Local and Systemic Adverse Events as a Measure of Safety and Tolerability","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"48","spread":null},{"groupId":"OG002","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"32","spread":null},{"groupId":"OG002","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"20","spread":null}]}]}]},{"type":"PRIMARY","title":"Immunogenicity of a Single Full (0.5 mL) Dose and a 0.25 mL 2-dose Regimen of Inflexal V, Using the EMA Guideline for the Re-registration of the Seasonal Influenza Vaccine in Adults (Aged ≥18 to ≤60 Years) as Reference","description":"Seroconversion rate","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.9","spread":null},{"groupId":"OG001","value":"95.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.0","spread":null},{"groupId":"OG001","value":"97.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.9","spread":null},{"groupId":"OG001","value":"86.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Immunogenicity of a Single Full (0.5 mL) Dose and a 0.25 mL 2-dose Regimen of Inflexal V, Using the EMA Guideline for the Re-registration of the Seasonal Influenza Vaccine in Adults (Aged ≥18 to ≤60 Years) as Reference","description":"GMT-fold increase - calculated as the GMT on Day 22 divided by the baseline GMT value","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.5","spread":null},{"groupId":"OG001","value":"19.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.6","spread":null},{"groupId":"OG001","value":"24.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.8","spread":null},{"groupId":"OG001","value":"14.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":102},"commonTop":["Pyrexia","Erythema (at the injection site)","Pyrexia","Pain (at the injection site)","Malaise"]}}}